IN8bio Strengthens Intellectual Property Portfolio with Newly Granted Global Patents
19 Setembro 2023 - 9:03AM
IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage
biopharmaceutical company focused on innovative gamma-delta T cell
therapies, today announced significant updates to its foundational
IP portfolio. The company was recently granted patents around the
world that cover use of the combination of its proprietary DeltEx
DRI platform with CAR-T and CPI’s.
IN8bio's DRI platform uses genetic engineering
to empower gamma-delta T cells with resistance to the killing
effects of chemotherapy enabling them to be more effective at
killing cancer cells. This innovative approach allows synergistic
combinations with standard-of-care chemotherapy regimens to
strengthen the immune response and broadly eliminate cancer cells.
The technology covered by the newly granted patents enhance the
therapeutic potential of DRI cells by enabling their integration
with CAR-T technology and CPIs, thereby bolstering the potential
effectiveness of the drug therapy against solid tumor cancers.
William Ho, CEO and co-founder of IN8bio,
stated, "Establishing a robust IP foundation is pivotal to the
successful growth and expansion of our business. Our proprietary
DRI technology, which generates chemotherapy-resistant cells,
allows for the synergistic combination with front-line
chemotherapies to break down barriers preventing a robust immune
response. Our technology, supported by these newly granted patents
opens avenues for expanding the application of these cells in
conjunction with CAR-T technologies and checkpoint inhibitors to
advance the fight against cancer. By harnessing these cells, we can
bring cell therapy to the forefront of treatment options and offer
new hope towards realizing our mission of achieving ‘Cancer Zero,’
our goal of pursuing the safe eradication of all tumor cells in
patients fighting cancer.”
IN8bio’s DRI platform has enabled a deep
pipeline of product candidates. The Company has initiated a Phase 2
clinical trial (NCT05664243) of a genetically modified autologous
gamma-delta T cell therapy, INB-400, targeting newly diagnosed
glioblastoma (GBM). The trial, cleared by the Food and Drug
Administration (FDA) in December 2022, will be conducted at
multiple centers across the United States and is open for
enrollment. IN8bio is also conducting Phase 1 clinical trials of
INB-200 for the treatment of newly diagnosed GBM and INB-100 for
the treatment of patients with leukemias undergoing haploidentical
stem cell transplantation (HSCT). Clinical updates in both programs
are expected to be presented at major medical meetings this
fall.
IN8bio boasts a strong IP portfolio of granted
patents encompassing the DRI, CAR-T and HSCT families, with
multiple additional applications pending globally to further expand
its patent portfolio and IP position.
About IN8bio
IN8bio is a clinical-stage biopharmaceutical
company focused on the discovery, development and commercialization
of gamma-delta T cell product candidates for solid and liquid
tumors. Gamma-delta T cells are a specialized population of T cells
that possess unique properties, including the ability to
differentiate between healthy and diseased tissue. IN8bio’s DeltEx
platform employs allogeneic, autologous, iPSC and genetically
modified approaches to develop cell therapies, designed to
effectively identify and eradicate tumor cells.
IN8bio is currently conducting two
investigator-initiated Phase 1 clinical trials for its lead
gamma-delta T cell product candidates: INB-200 for the treatment of
newly diagnosed glioblastoma and INB-100 for the treatment of
patients with hematologic malignancies undergoing haploidentical
hematopoietic stem cell transplantation. IN8bio is initiating
INB-400, a company-sponsored multi-center Phase 2 clinical trial in
newly diagnosed glioblastoma, which received IND clearance in late
2022. IN8bio also has a broad portfolio of preclinical programs
focused on addressing other hematological and solid tumor cancers.
For more information about IN8bio and its programs, please visit
www.IN8bio.com.
Forward Looking Statements
This press release may contain forward-looking
statements made pursuant to the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. These statements
may be identified by words such as “aims,” “anticipates,”
“believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,”
“intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will”
and variations of these words or similar expressions that are
intended to identify forward-looking statements, although not all
forward-looking statements contain these words. Forward-looking
statements in this press release include, but are not limited to,
statements regarding the development and continued progress and
success of our preclinical and clinical trials and programs and
product candidates; IN8bio’s success in pending and future patent
applications; the timing of initiation, progress and scope of
clinical trials; the synergistic potential of DeltEx gamma-delta T
cells and chemotherapy to target solid tumors; the therapeutic
potential of DRI cells integrated with CAR-T technology and CPIs;
IN8bio’s progress towards and achievement of its goal of “Cancer
Zero”; and IN8bio’s ability to achieve anticipated milestones,
including expected data readouts from its trials, enrollment of
additional patients in its clinical trials, advancement of clinical
development plans and to develop new preclinical programs. IN8bio
may not actually achieve the plans, intentions or expectations
disclosed in these forward-looking statements, and you should not
place undue reliance on these forward-looking statements. Actual
results or events could differ materially from the plans,
intentions and expectations disclosed in these forward-looking
statements as a result of various factors, including: risks to site
initiation, clinical trial commencement, patient enrollment and
follow-up, as well as IN8bio’s ability to meet anticipated
deadlines and milestones; uncertainties inherent in the initiation
and completion of preclinical studies and clinical trials and
clinical development of IN8bio’s product candidates; the risk that
IN8bio may not realize the intended benefits of its DeltEx
platform; availability and timing of results from preclinical
studies and clinical trials; whether the outcomes of preclinical
studies will be predictive of clinical trial results; whether
initial or interim results from a clinical trial will be predictive
of the final results of the trial or the results of future trials;
the risk that trials and studies may be delayed and may not have
satisfactory outcomes; potential adverse effects arising from the
testing or use of IN8bio’s product candidates; expectations for
regulatory approvals to conduct trials or to market products;
IN8bio’s reliance on third parties, including licensors and
clinical research organizations; and other important factors, any
of which could cause our actual results to differ from those
contained in the forward-looking statements. These and other
factors are described in greater detail in the section entitled
“Risk Factors” in our Quarterly Report on Form 10-Q filed with the
Securities and Exchange Commission (SEC) on August 10, 2023, as
well as in other filings IN8bio may make with the SEC in the
future. Any forward-looking statements contained in this press
release speak only as of the date hereof, and IN8bio expressly
disclaims any obligation to update any forward-looking statements
contained herein, whether because of any new information, future
events, changed circumstances or otherwise, except as otherwise
required by law.
Company Contact:IN8bio, Inc.Patrick McCall+ 1
646.600.6GDT (6438)info@IN8bio.com
Investors & Media Contact: Argot
PartnersIN8bio@argotpartners.com
IN8bio (NASDAQ:INAB)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
IN8bio (NASDAQ:INAB)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024